Acriptega
A Tenofovir/Lamivudine/Dolutegravir brand by Aurobindo Pharma — tablet, made in India.
Ogbogwu is a reference directory quoting the NAFDAC register. We do not sell, dispense or prescribe medicines, and nothing here replaces a doctor or pharmacist.
NAFDAC registration
Our October 2026 copy of the NAFDAC Greenbook lists Acriptega Tablets — registration number B4-9927, applicant Healthline Limited — with status Active.
The applicant is the Nigerian company that holds the NAFDAC registration for this product — for imported brands this is often a local distributor rather than the maker.
Acriptega price in Nigeria
Prices for Tenofovir/Lamivudine/Dolutegravir products vary by brand, strength, and pack size — check current prices at a licensed pharmacy, or tell us what you need and we'll connect you with a verified source.
Which one are you?
I'm buying Acriptega
Tell us what you need and the quantity, and we'll connect you with a verified, NAFDAC-registered source. Free, no obligation.
I sell Acriptega
Get a free page where buyers look for them: your products, your number, how to find your shop. Independent of NAFDAC and government. Nothing goes live until you have seen it and approved it. Why list? →
See a listed shop: Blessed Michael Pharmacy → · or sign up yourself →
Acriptega at a glance
- Generic name
- Tenofovir/Lamivudine/Dolutegravir
- Manufacturer
- Aurobindo Pharma
- NAFDAC applicant
- Healthline Limited
- Made by (factory)
- Mylan Laboratories Limited
- Form
- Tablet
- Composition
- Dolutegravir 50 mg
- Lamivudine 300 mg
- Tenofovir Disoproxil Fumarate 300 mg
- Made in
- India
- NAFDAC reg. no.
- B4-9927
About Tenofovir/Lamivudine/Dolutegravir
Tenofovir/Lamivudine/Dolutegravir, commonly known as TLD, is a fixed-dose combination antiretroviral tablet used for the treatment of HIV-1 infection. It combines three powerful antiretroviral medicines into a single pill: Tenofovir disoproxil fumarate (300mg), an NRTI that blocks the HIV reverse transcriptase enzyme; Lamivudine (300mg), another NRTI that works similarly to tenofovir but targets a different step in viral replication; and Dolutegravir (50mg), an integrase strand transfer inhibitor (INSTI) that prevents HIV from inserting its genetic material into human cells. Nigeria has the second largest HIV burden in the world, with approximately 1.9 million people living with HIV, and TLD has become the cornerstone of the national antiretroviral therapy programme. The shift to TLD represents a major advance in HIV treatment in Nigeria, offering superior viral suppression with fewer side effects compared to older regimens.
Read the full Tenofovir/Lamivudine/Dolutegravir guide — dosage, side effects, warnings, and all registered brands.
Frequently asked questions
Registration details are shown exactly as recorded in the NAFDAC Greenbook (our copy: October 2026). Listings can lag renewals — always confirm current status on the official Greenbook before acting on it. Content updated October 2026.